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Summary
 
It has been proposed that some bystander T cell activation may in fact be due to T cell antigen
receptor (TCR) cross-reactivity that is too low to be detected by the effector cytotoxic T lym-
phocyte (CTL). However, this hypothesis is not supported by direct evidence since no TCR
ligand is known to induce T cell proliferation and differentiation without being recognized by
the effector CTL. Here we report that transgenic T cells expressing a T cell receptor to influ-
enza virus A/NT/68 nucleoprotein (NP) 366-374:D
 
b
 
 complexes clonally expand and become
effector CTLs in response to homologous peptides from either A/PR8/34 (H1N1), A/AA/60
(H2N2), or A/NT/68 (H3N2). However, the effector T cells induced by each of the three
peptides kill target cells pulsed with NP peptides from the H3N2 and H2N2 viruses, but not
from the H1N1 virus. Thus, NP366–374 from influenza virus H1N1 is the first TCR ligand
that can induce T cell proliferation and differentiation without being recognized by CTLs.
Since induction of T cell proliferation was mediated by antigen-presenting cells that express
costimulatory molecules such as B7, we investigated if cytolysis of H1N1 NP peptide–pulsed
targets can be restored by expressing B7-1 on the target cells. Our results revealed that this is
the case. These data demonstrated that costimulatory molecule B7 modulates antigen specificity
of CTLs, and provides a missing link that explains some of the bystander T cell activation.
 
B
 
ystander activation of T cells, or the expansion and
functional differentiation of T cells with no apparent
reactivity to the immunizing antigen, has been described in
several models (1–5). Several groups have recently revisited
the mechanisms of bystander T cell activation, and at least
two hypotheses have been proposed (6–8). First, bystander
activation may be due to nonspecific effects of cytokines
with no involvement of TCR recognition. This hypothesis
is supported by a recent report that type 1 interferon in-
duced by virus can induce T cell proliferation and/or ac-
quisition of memory cell markers (6). Second, bystander T
cell activation may be due to antigen-driven proliferation
of lymphocytes, but such cross-reactivity is too low to be
detected by conventional cytotoxic T cell assay. Recent
studies using transgenic T cells demonstrated that if the
TCR is definitely unrelated to the challenging antigen,
then bystander T cell activation is insignificant during CTL
immune responses (7, 8). Although the findings in this
study favor the second hypothesis, it remains to be demon-
strated if there are low-affinity TCR ligands that induce T
cell proliferation and maturation but not cytolysis.
TCR ligand density required for inducing T cell prolif-
eration and IL-2 production appears to be significantly
higher than that required for cytolysis (9, 10). These find-
ings (9, 10) demonstrated that the total number of signals
required for the induction is higher than that required to
trigger the effector function. However, to compare the re-
quirement for TCR ligand density it was necessary to use the
same cells both as targets for cytolysis and as stimulators for
T cell activation (9, 10). The professional APCs that induce
the immune response are distinct from the cells on which
the effector function of the CTL is executed. One of the
distinct features is that APCs express multiple costimulatory
molecules, the most potent of which are B7 family mem-
bers B7-1 and B7-2 (for review see reference 11), whereas
most target cells used for CTL assay do not express B7
molecules at significant levels. Since B7-CD28/CTLA4 in-
teraction has been demonstrated to reduce the threshold for
T cell activation (12), it is possible that some TCR ligands
that cannot trigger cytolysis in the absence of B7 may do so
in its presence. In this study, we compared the specificity of
a TCR in the induction of T cell proliferation, differentia-
tion into effector CTL, and cytolysis of target cells. We re-
port here a viral peptide that induces clonal expansion and
functional maturation of CD8 T cells without triggering
cytolysis in CTL assay. These data provide the first direct
evidence that clonal expansion and functional maturation
of T cells can be induced by a ligand whose cross-reactivity
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cannot be detected by a conventional CTL assay. More im-
portantly, expression of B7-1 on the target cells restores
CTL recognition of the viral peptide. These data demon-
strate that costimulation by B7 modulates CTL specificity,
and provide a missing link that explains some bystander T
cell activation.
 
Materials and Methods
 
Experimental Animals.
 
F5 transgenic mice (13) expressing T
cell receptor for influenza nucleoprotein (NP) peptide 366–374
and F5 mice with a targeted mutation of the RAG-1 gene (14)
were provided by Dr. Eugenia Spanopoulou (Mt. Sinai Medical
Center, New York). C57BL/6 mice were purchased from The
Jackson Laboratory (Bar Harbor, ME). Generally, 6–12-wk-old
mice were used for the study, except for the Rag-1–deficient
mice, which were used at the age of 4 wk old.
 
Viral Peptides.
 
Three influenza viral peptides were used for
this study. An L
 
d
 
-binding tumor antigen P1A peptide was used as
the control in most experiments. The sequences, viral origin, and
viral subtypes of the peptides are listed in Table 1. All peptides
were synthesized by Research Genetics (Huntsville, AL). Al-
though influenza viruses of the same subtype can have different
NP sequences, for simplicity we have used the subtypes to indi-
cate the peptide used for the study.
 
Transfection of EL4 Cells.
 
EL4 cells were transfected with ei-
ther pSV vector or the pSV vector containing murine B7-1
cDNA as has been previously described (15). After selecting with
G418 (0.6 
 
m
 
g/ml), the viable cells were screened for B7-1 expression
using anti–B7-1 mAb 3A12 (16). A single clone expressing a high
level of B7-1 and a control drug-resistant clone, EL4-Neo, were
used for the study.
 
Proliferation of T Cells to Antigenic Peptides.
 
Total spleen cells
(2 
 
3
 
 10
 
5
 
/well) from F5 transgenic mice were cultured with the
given concentrations of peptides in Click’s EHAA medium for 48 h.
In some experiments, 10
 
4
 
/well of RAG-1–deficient F5 transgenic
spleen cells and 2 
 
3
 
 10
 
5
 
 mitomycin C–treated C57BL6/j spleen
cells were stimulated by given concentration of the viral peptides
for 72 h. The proliferation of T cells was determined by incorpo-
ration of [
 
3
 
H]TdR pulsed (1.25 
 
m
 
Ci/well) during the last 6 h of
culture. The data presented are means of duplicates with variation
from the means 
 
,
 
15%.
 
CTL Assay.
 
For target cells, we used EL-4 (H-2
 
b
 
) target
cells, or EL-4- cells transfected with either vector alone (EL4-
Neo) or with B7-1 (EL4-B7). These targets were labeled with
 
51
 
Cr for 1 h at 37
 
8
 
C. After three washes, the labeled target cells
were added to a 96-well plate containing varying concentrations
of synthetic peptides corresponding to amino acid (AA) 366–374
of influenza virus nucleoprotein or a control peptide. The effec-
tor cells were added and incubated for 6 h, and the released 
 
51
 
Cr
in the supernatants was determined. The specific percentage of
lysis was calculated by the following formula: Specific % lysis 
 
5
 
[(cpm
 
samples
 
 
 
2
 
 cpm
 
medium
 
)/(cpm
 
maxim
 
 
 
2
 
 cpm
 
medium
 
)] 
 
3
 
 100. As ef-
fector cells, we used spleen cells (0.5 
 
3
 
 10
 
6
 
/ml) from F5 trans-
genic mice after they were stimulated with 0.1 
 
m
 
g/ml of viral
peptides for 4 d in vitro.
 
Results and Discussion
 
Split Responses of F5 Transgenic T Cells to NP Peptides from
H1N1 Virus.
 
The 
 
a
 
 and 
 
b
 
 chains for TCR in the F5
transgenic mice were cloned from a CTL clone, F5, which
kills target cells pulsed with peptide from a H3N2 virus
(NP366–374) but not those pulsed with the homologous
peptide from a H1N1 virus (17). To test whether naive
transgenic T cells have the same specificity, we isolated
spleen cells from the F5 mice and tested their proliferative
responses to the NP366–374 peptides from H1N1, H2N2,
and H3N2 virus. The NP peptides from H3N2 and H1N1
viruses each differ from H2N2 NP peptide in one amino
acid, at either position 7 or 8. As shown in Fig. 1 
 
a
 
, the
H1N1 NP peptide induces significant proliferative re-
sponses of the transgenic T cells. However, 100-fold more
H1N1 peptide than H3N2 peptide is needed to achieve
similar levels of proliferation. Interestingly, H2N2 NP pep-
tides are 
 
z
 
100-fold more efficient than the peptide from
H3N2 virus that induced the F5 T cells in the first place.
 
Table 1.
 
Sequence of Peptides Used in this Study
 
Origin Viral subtype
Peptide sequence
(366–374)
A/PR8/34 H1N1 ASNENMETM
A/Ann Arbor/60 H2N2 ASNENMDTM
A/NT/68 H3N2 ASNENMDAM
P1A (AA35–43) control LPYLGWLVF
Figure 1. Split responses of
the F5 transgenic T cells to pep-
tides corresponding to AA366–
374 of nucleoprotein from influ-
enza virus A/PR8/34 (H1N1),
A/Ann Arbor/60 (H2N2), and
A/NT/68 (H3N2). (a) Prolifera-
tive T cell response. F5 spleen
cells (2 3 105/well) were stimu-
lated with given concentration of
the viral peptides or control P1A
peptides for 48 h. Proliferation of
T cells was determined by incor-
poration of [3H]TdR pulsed dur-
ing the last 6 h of culture. (b) Specificity of activated F5 CTLs. F5 spleen cells (5 3 105/ml) were stimulated with 0.1 mg/ml of the H3N2 NP peptide
for 4 d. Viable cells were isolated and used as effector cells. EL4 cells were labeled using 51Cr and added to 96-well plates containing varying concentra-
tions of peptides. Effector/target ratio is 60:1 for all groups. 
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The proliferation is specific, as control peptide from a tu-
mor antigen P1A, which binds H-2L
 
d
 
 but not D
 
b
 
, induces
no proliferative responses at all doses tested.
Next we activated the spleen cells with the H3N2 NP
peptide and tested the specificity of the effector T cells. As
shown in Fig. 1 
 
b
 
, the F5 effector T cells efficiently lysed
the target cells pulsed with either H3N2 or H2N2 NP pep-
tides, but at all doses tested no lysis of the H1N1 NP pep-
tide–pulsed target cells was detected. A comparison of the
dose responses in Fig. 1, 
 
a
 
 and 
 
b
 
, reveals that differential
specificity of the F5 T cells detected by proliferation and
CTL assay was not due to the differential sensitivity of the
assays. First, with regards to the doses of peptides, the sensi-
tivities of both assays were very similar; 50% maximal re-
sponse was achieved at 10
 
2
 
3
 
 
 
m
 
g/ml of H3N2 peptide and
10
 
2
 
5
 
 
 
m
 
g/ml of H2N2 peptide. Second, in proliferation as-
say, it took only 100-fold more H1N1 than H3N2 peptide
to induce a comparable proliferation as the H3N2 peptides,
whereas 10,000-fold more H1N1 peptide than is required
for maximal lysis of H3N2 peptide–pulsed targets still does
not trigger cytolysis.
The difference in the ability of the three peptides to in-
duce F5 T cell proliferation and sensitize target cell lysis by
CTL may be due either to the differential ability of these
peptides to bind H-2D
 
b
 
, or to differential recognition of
these peptides by the F5 TCR. We performed RMA-S
D
 
b
 
-stabilization experiments to differentiate these possibili-
ties. RMA-S cells lack functional TAP(transporter associ-
ated with antigen processing)-2 gene, and express empty
MHC class I that can be stabilized by adding exogenous
peptides (18). MHC stabilization assay has been widely
used to measure MHC–peptide interaction on live cells. As
shown in Fig. 2, NP peptides from H1N1 and H2N2 vi-
ruses are comparable in stabilizing H-2D
 
b
 
, whereas the
peptide from H3N2 virus is 
 
z
 
100-fold less efficient. Thus,
the difference between the H3N2 and H2N2 NP peptides
at position 8 affects their ability to bind D
 
b
 
, whereas the
difference between the H1N1 and two other NP peptides
at position 7 affects F5 TCR recognition. This is consistent
with the three-dimensional structure of D
 
b
 
:NP peptide
complex (19) in which the main chain and part of the side
chain of the H1N1 peptide at position 8 are buried in the
MHC, and residue E at position 7 is fully accessible to sol-
vent. It is therefore likely that the unique split T cell re-
sponse to the H1N1 NP peptide is caused by TCR ligand
structure rather than ligand density.
Since most of the experiments were carried out in trans-
genic mice which may undergo endogenous V-D-J/V-J
rearrangement, it is possible to explain the distinct specific-
ity at the inductive and the effector phase by postulating
the existence of two populations of T cells: one expresses
the transgenic receptors that have the specificity of the
original F5 clones, whereas the other gains the specificity
for the H1N1 peptide as a result of pairing a transgenic
TCR chain with an endogenous chain. We used spleen
cells from the Rag-1
 
2
 
/
 
2
 
 F5 mice as the responder T cells to
rule out this possibility. Again, the H1N1 NP peptide in-
duces significant proliferation of the Rag-1–deficient F5 T
cells (Fig. 3). This result confirmed that the F5 TCR has
reactivity to the H1N1 NP peptide.
To test if all three related peptides are capable of induc-
ing cytotoxicity from the transgenic T cells, we stimulated
F5 spleen cells with NP peptides from all three strains of
influenza viruses and tested the influenza-specific CTLs
generated. In addition, we also compared the fine specific-
ity of the CTL generated in each culture by using a target
cell pulsed with three NP peptides and an unrelated control
peptide. As shown in Fig. 4, 
 
a
 
–
 
c
 
, all three influenza pep-
tides induce mature CTLs capable of lysis H3N2 and
H2N2 NP peptide–pulsed targets. These results demon-
strated that the H1N1 NP peptide is capable of inducing
the maturation of CTLs. Furthermore, although the H1N1
NP peptide-induced CTL is less potent than those induced
by the H2N2 and H3N2 NP peptides, the relative lysis of
the CTL towards three different peptides remains the same.
These results substantiate the notion that T cells with the
same fine specificity are stimulated by three different NP
peptides.
Taken together, the results presented in this section indi-
cate that NP 366–374 from the H1N1 virus can induce F5
T cell proliferation and maturation into CTLs. However,
the F5 CTL cannot recognize target cell pulsed with the
H1N1 NP peptide. To our knowledge, this is the first
TCR ligand known to have such properties. This type of
TCR ligand can be the underlying cause of some of the so-
called bystander T cell activation in vivo.
 
Modulation of CTL Specificity by Costimulatory Molecule
B7-1.
 
Proliferation assays used spleen accessory cells ex-
pressing multiple costimulatory molecules. In contrast, the
Figure 2. Relative Db-binding
activity of the viral peptides used
for the study as determined by
MHC stabilization assay using
RMA-S cells. RMA-S cells
(105/well) were incubated over-
night with varying concentra-
tions of viral peptides in RPMI
medium containing 20% FCS.
The cell surfaces of H-2Db were
determined by flow cytometry
using biotinylated anti-Db mAb
(KH95) and PE-labeled strepta-
vidin. Data presented are mean fluorescences, as measured by flow cy-
tometry. The dotted line indicates expression of Db in the absence of ex-
ogenous peptide.
Figure 3. Proliferation of
RAG-12/2 F5 T cells to NP
peptides from all three strains of
influenza viruses. RAG-12/2
spleen cells (104/well) were stim-
ulated by varying concentrations
of the viral peptides and 2 3 105
mitomycin C–treated syngeneic
spleen cells per well as accessory
cells. The dotted line depicts T
cell proliferation when no pep-
tide is added. 
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CTL assay used EL4 thymoma devoid of costimulatory ac-
tivity as targets (20). Therefore, it is possible that the split T
cell response was due to the presence or absence of costim-
ulatory activity in the cells used to measure cross-reactivity.
To test this possibility, we transfected B7-1 into the EL4
cells. As shown in Fig. 5 
 
a
 
, EL4 cells transfected with vec-
tor alone have no detectable B7-1, while B7-1–transfected
EL4 cells express high level of B7-1. Therefore, we com-
pared cytolysis of EL4-Neo and EL4-B7 in the presence of
various viral peptides. As shown in Fig. 5 
 
b
 
, EL4-Neo cells
are lysed in the presence of H2N2 and H3N2 NP peptides,
but not in the presence of H1N1 or control P1A peptides.
In contrast, EL4-B7 targets are lysed in the presence of
H1N1 NP peptide. Thus, expression of B7-1 on target cells
restores F5 CTL recognition of H1N1 NP peptide–pulsed
target cells. To our knowledge, this is the first evidence that
costimulation by B7-1 modulates CTL specificity.
It has been demonstrated that costimulatory molecule B7
reduces the threshold of signals required for T cell activa-
tion, as evidenced by the reduction of density (12) and du-
ration (21) of the ligand required to trigger a TCR in the
presence of T cell costimulation. Moreover, we (15) and
others (22, 23) have shown that costimulation enhances
CTL effector function in vitro and in vivo in antitumor
immunity and autoimmunity. The results presented here
extend this notion by showing that one outcome of lower-
ing the threshold of T cell activation is to increase cross-
reactivity of TCRs.
Despite the recent interest in the subject (6–8), the mo-
lecular basis for bystander T cell activation remains unclear.
Tough et al. (6) reported massive proliferation of memory
CD8 T cells mediated by type 1 interferon, which is pro-
duced in response to viral infection. Ehl et al. (7) showed
that when the overwhelming number of naive T cells are
specific for an unrelated antigen, a low level of bystander
CTL activation, mediated by IL-2, can be detected. How-
ever, Ehl et al. concluded that this level of bystander activa-
tion is unlikely to be biologically significant in nontrans-
genic systems. Zarozinski and Welsh (8) demonstrated that
minimal proliferation of T cells that are not cross-reactive
to the challenging antigen during a strong immune re-
sponse, and, by inference, suggested that the majority of T
cell expansion during viral infection must be due to some
degree of TCR engagement. Our study demonstrates that
presence of costimulatory molecules, such as B7-1, on the
target cells, can increase the sensitivity of TCR for low-
affinity ligands. Given the existence of multiple costimula-
tory molecules on the professional APCs (for review see
Figure 4. Induction of cytotoxicity of F5 T cells by viral peptides. Fine specificity of T cells induced by three different peptides. RAG-11/1 F5 spleen
cells (5 3 105/ml) were stimulated with 0.1 mg/ml of H1N1 (a), H2N2 (b) or H3N2 (c) viral peptides for 4 d, and the viable cells were isolated and used
as effectors. Effector/target ratio is 60:1 for all groups. See Fig. 1 legend for details.
Figure 5. Modulation of
CTL specificity by costimula-
tory molecule B7-1. (a) Expres-
sion of B7-1 in EL4 cells trans-
fected with vector alone (top) or
B7-1 cDNA (bottom). Data pre-
sented are FACS“ histograms of
fluorescences in the presence
(solid lines) and absence of anti–
B7-1 mAb 3A12. (b) Fine speci-
ficity of F5 CTL using EL4-Neo
or EL4-B7 targets. See Fig. 1 leg-
ends for details of the CTL assay. 
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reference 11), the conclusion from this study provides a
mechanism by which viral antigens induce TCR-mediated
expansion of multiple T cell clones, even if their TCR–
cross-reactivity is too low to be detected by conventional
CTL assays.